AFP Gastric or Gastroesophageal Junction Adenocarcinoma
3 clinical trials · Condition
◉ Watch AFP Gastric or Gastroesophageal Junction Adenocarcinoma
| Record | Firm | Date |
|---|---|---|
| Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma (NCT07515625) | Fudan University | 2026-04-01 |
| Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC) (NCT07289997) | Hebei Medical University Fourth Hospital | 2025-09-28 |
| Sintilimab Plus Apatinib and SOX as First-line Treatment in Patients With AFP Gastric or Gastroesophageal Junction Adenocarcinoma (NCT06973330) | Anhui Provincial Cancer Hospital | 2025-07-01 |
Track AFP Gastric or Gastroesophageal Junction Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.